VIVA BIOTECH (01873) announced that Arthrosi Therapeutics has informed the company that on December 13, 2025, the buyer, Sobi US Holding Corp., agreed to acquire Arthrosi Therapeutics through a merger. Following the completion of the transaction, the company will no longer hold any equity in Arthrosi Therapeutics. The merger agreement stipulates an upfront payment of $950 million (subject to customary adjustments) and contingent consideration of up to $550 million.

Arthrosi Therapeutics is a Delaware-based clinical-stage biotech company focused on developing pozdeutinurad, a potential best-in-class, highly efficient, and selective next-generation URAT1 inhibitor designed to reduce serum uric acid levels, minimize acute flares, and decrease tophi in progressive gout patients.

As of the announcement date, VIVA BIOTECH's incubator held approximately 3.14% of Arthrosi Therapeutics' equity (on a fully diluted and converted basis). The board believes the merger allows the group to realize the long-term accumulated investment value in Arthrosi Therapeutics and presents an opportunity to enhance the group's financial flexibility.

Proceeds from the merger will be used to supplement the group's working capital and support the growth and development of other investment and incubation businesses.